Study Found Chemotherapy Drugs Capecitabine May Be Able to S

Release time:2017-11-02 13:40:04

  Recently, researchers from the London Cancer Institute through the study found that chemotherapy drugs capecitabine may be able to significantly improve the life quality of cancer patients. And it also serves as a new alternative strategy (to replace the CMF strategy) to help prevent breast cancer recurrence (after the treatment with Epirubicin). Researchers said that after surgical treatment, there are about 4,400 clinical trials in patients after follow the treatment of capecitabine began to use chemotherapy drugs epirubicin for treatment. They found that the drug capecitabine allowed the patient to experience fewer side effects and improved the quality of life of the patient.

       Related research published in the international magazine The Lancet Oncology。

       No matter what kind of treatment, patients will experience some side effects. But patients who undergo CMF therapy tend to experience fewer side effects. Including early menopause, Nausea, infection, thrombosis and anemia and so on. During clinical trials, patients were often tracked 12, 18, and 24 months, and followed by a 10-year follow-up survey. The purpose of the investigator is to observe whether the patient's cancer will recur and monitor the side effects of the patient. The results show that at least 5 years, more than 85% of patients have not experienced cancer recurrence.

       Researcher Professor Judith Bliss said that the ongoing TACT2 trial is a larger singularity study aimed at observing the benefits of different therapies in the treatment of breast cancer. The result shows that capecitabine can serve as a replacement CMF strategy to improve the life quality  of patients without compromising the risk of survival. In addition, the researchers also examined whether the accelerated treatment course of the drug Epirubicin (every two weeks to replace the original every three weeks) can effectively improve the patient's tolerance. But the results show that this does not seem feasible. The current clinical trial is to elucidate deeply the effect of accelerated chemotherapy on the late stages of the patient, while assessing the symptoms and side effects of some patients.

       Professor David Cameron said that it may be important to analyze the data reported by the patient because we were able to clarify the patient's tolerance for therapy and how they handled the situation during therapy. This new type of chemotherapy may be beneficial for a range of breast cancer patients, including young women who want to protect the body's fertility and so on. The current treatment of breast cancer therapy is very successful. And for researchers, it is important to delve into how to improve patient experience and reduce the side effects of therapy. The results of future clinical trials will significantly help physicians make the best treatment for patients with chemotherapy.